


# Fact Sheet *Targeting, Attacking & Eradicating Cancer*

JENNEREX, INC. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. Jennerex's lead product candidate, JX-594, which can be delivered both intratumorally and intravenously, and is currently in an international, randomized, Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. Preliminary clinical data have shown selective tumor cell killing as well as a good tolerability profile. The company is planning for late-stage clinical trials and continues to evaluate JX-594's promising applicability to multiple tumor types. Clinical trials of JX-594 in colorectal cancer are also under way. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy.

*Four trials completed. Three ongoing. Over 115 patients treated to date.*

Products	Preclinical	Phase 1	Phase 2	Phase 3
JX-594				
Liver	[Progress bar spanning Preclinical, Phase 1, and Phase 2]			
Colorectal	[Progress bar spanning Preclinical and Phase 1]			
JX-929				
Pancreatic	[Progress bar spanning Preclinical and Phase 1]			
Breast	[Progress bar spanning Preclinical and Phase 1]			
JX-1395				
Prostate	[Progress bar in Preclinical]			
JX-Next Generation				
Various	[Progress bar in Preclinical]			



## RECENT MILESTONES

- ▶ Published clinical proof-of-concept of JX-594 in journal, *Nature*.
- ▶ Entered an exclusive partnership for the development and commercialization of JX-594 in Europe.
- ▶ Demonstrated survival benefit in Phase 2 JX-594 trial in liver cancer. Phase 2b trial under way.
- ▶ Made five key management additions: Lara Longpre, COO; Greg Schafer, CFO; James Burke, MD, VP of Clinical Research; Mark Backer, SVP of Technical Ops.; Ursula Fritsch, PharmD., VP of Reg. Affairs and QA.
- ▶ Presented Phase 1 clinical data showing safe and effective intravenous delivery of JX-594.
- ▶ Presented Phase 2 JX-594 data showing increased survival in advanced liver cancer.

## JENNEREX AT A GLANCE

- ▶ Private, clinical-stage biotech company
- ▶ Three clinical-stage product candidates for cancer
- ▶ Headquartered in San Francisco, CA
- ▶ R&D operations in Canada & South Korea
- ▶ Over \$55mm raised to date through private financings
- ▶ Strategic regional partnerships
- ▶ Approx. 35 employees


## CONTACT US

Jennifer Cook Williams  
Investor Relations  
Office: 360-668-3701  
Jennifer@cwcomm.org

Jennerex, Inc.  
450 Sansome Street, 16th Floor,  
San Francisco, CA, 94111  
www.jennerex.com

# Our first-in-class products wage a multipronged attack on cancer.


Jennerex's products are designed using proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform. SOLVE takes advantage of the natural attributes of poxviruses as well as their ability to be genetically engineered to produce safe, therapeutic viruses that can infect solid tumors both systemically and locally. SOLVE platform has the ability to produce novel, multi-functional products, such as JX-594, that can selectively express high concentrations of complementary therapeutics. We plan to continue employing SOLVE to create new therapeutics that broadly target different types of cancers in our early-stage pipeline.



David H. Kirn and Steve H. Thorne (2009). Nature Reviews Cancer. Vol 9, 65.

## JX-594 – ERADICATES CANCERS REFRACTORY TO STANDARD THERAPIES

- ▶ Cancer biotherapeutic derived from a proprietary breakthrough class of targeted and armed oncolytic vaccinia viruses.
- ▶ Currently in Phase 2 trials. Late-stage trials being planned.
- ▶ Interim Phase 2 data demonstrated increased survival in high-dose group vs. low dose group in advanced liver cancer.
- ▶ Excellent safety profile (transient flu-like symptoms) when compared with standard of care.
- ▶ Both intratumoral and intravenous delivery have resulted in anti-cancer effects across multiple cancer types.
- ▶ JX-594 is genetically modified by deleting its thymidine kinase gene to enhance cancer selectivity and is armed with GM-CSF gene to stimulate systemic anti-tumoral tumoral immune response.



**Jennerex virus JX-594 eradicates a liver cancer tumor metastasis in neck (as shown via photos and corresponding PET scan images).**

## MANAGEMENT TEAM & BOARD

### Executive Management Team

Ken Newport, C.A., M.Acc. - Director & Acting Chief Executive Officer  
 John Bell, Ph.D. - Chief Scientific Officer & Director  
 David H. Kirn, M.D. - Founder, President, Chief Medical Officer & Director  
 Lara Longpre, M.Sc., M.B.A. - Chief Operating Officer  
 Greg Schafer, M.B.A. - Chief Financial Officer  
 Mark P. Backer, Ph.D. - SVP, Technical Operations

Helena Chaye, Ph.D., LL.B. - VP, Corporate Affairs & Intellectual Property  
 Ursula Fritsch, PharmD. - VP, Regulatory Affairs  
 Tae-Ho Hwang, DDS, Ph.D. - Research Advisor & Head of Pusan Research Site  
 James Burke, M.D. - VP, Clinical Research  
 Lucy Chang, Ph.D. - VP, Quality and Analytical Development  
 Samantha Miller, M.Sc., M.B.A. - VP, Corporate Development

### Board of Directors

Brennan R. Mulcahy, LL.D., Chairman of Jennerex & CEO of American Solar Direct  
 John Bell, Ph.D., Chief Scientific Officer of Jennerex  
 Peter D. Charbonneau, M.B.A., Gen. Partner, Skypoint Capital Corp.  
 Terry Hermiston, Ph.D., VP, Biologics Research, Bayer HealthCare  
 Hoyoung Huh, M.D., Ph.D., Chairman of Geron & BiPar Sciences

David Kirn, M.D., Founder, President and Chief Medical Officer of Jennerex  
 Ken Newport, C.A., M.Acc., Acting Chief Executive Officer of Jennerex  
 Hartley S. Stern, M.D., FRCS(C) FACS, Exec. Dir., Jewish General Hospital & Professor of Surgery, McGill University  
 Glen Sato, J.D., M.B.A., Corporate Counsel, Partner, Cooley, LLP

## COMMITTED TO REACHING PATIENTS GLOBALLY THROUGH KEY PARTNERSHIPS

- Transgene:** Exclusive license to develop and commercialize JX-594 in Europe and neighboring countries.
- Green Cross Corporation:** Exclusive license to develop and commercialize JX-594 in South Korea.
- Lee's Pharmaceutical Ltd.:** Exclusive license to develop and commercialize JX-594 in China.